EFFICACY OF TYPE 2 SODIUM-GLUCOSE COTRANSPORTER INHIBITORS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AGAINST THE BACKGROUND OF INSULIN RESISTANCE

Аннотация

Introduction: The development of non-alcoholic fatty liver disease NAFLD, and hence insulin resistance, then type 2 diabetes mellitus in obese patients is of great importance in the choice of treatment tactics, duration, and possible ambiguous outcomes in the progression of NAFLD. Recent evidence suggests that sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of non-alcoholic steatohepatitis in humans, as well as improve liver steatosis in obese patients with type 2 diabetes. Purpose: To evaluate the effectiveness of SGLT2 inhibitors in patients with NAFLD on the background of insulin resistance Research materials and methods: we used 10 mg of dapagliflozin for 3 months in 30 patients with non-alcoholic fatty liver disease aged 20-65 years. The diagnosis of NAFLD was established by abdominal ultrasound. All patients underwent biochemical and anthropometric studies, bio impedance measurement, abdominal ultrasound before and after treatment, as well as a comparative analysis. Research results: The average age of patients was 44.33+8.2 years. Of the 30 patients, 18 were men and 12 were women. In a comparative analysis, we observed a significant decrease in the biochemical markers of liver damage (ALT, GGT), insulin, and the index of insulin resistance. Bioimpedance measurement indicators (total fat, visceral fat. The average body mass index significantly decreased: at admission, the average was 31.05±3.44, after treatment it decreased to 28.9±2.34 (p<0.05). Conclusion. Our study showed the potential efficacy of an SGLT-2 inhibitor in NAFLD in patients without diabetes mellitus. The results showed a significant improvement in biochemical parameters, insulin sensitivity, lipid profile, body component composition, and weight loss during dapagliflozin therapy for NAFLD.